Gritstone Oncology racks up $102 mln Series A

By Iris Dorbian — 4 months ago

San Francisco Bay area-based Gritstone Oncology, a cancer immunotherapy company, has raised $102 million in Series A financing. The investors included Versant Ventures, The Column Group, Clarus Ventures, Frazier Healthcare Partners, Redmile Group, Casdin Capital and Transformational Healthcare Opportunity.

Continue

Clarus Ventures and Novo A/S back Nuvelution

By Iris Dorbian — 7 months ago

Clarus Ventures and Novo A/S have provided an undisclosed investment in Nuvelution Pharma Inc. In addition to the funding, Nuvelution has named Dr. Barry Gertz and Dr. James Cornwall as chief physician scientist and chief business officer, respectively. Based in South San Francisco, Nuvelution is a solutions provider for R&D companies in the pharmaceutical and biotech industries to improve their productivity.

Continue

Annexon Bioscience racks up $34 mln

By Iris Dorbian — 1 year ago

Annexon Bioscience has raised $34 million in Series A-1 funding. Novartis Venture Funds led the round with participation from Satter Investment Management and Clarus Ventures. Based in Redwood City, Calif., Annexon Bioscience is a developer of pathway inhibitors that treat neurodegenerative and autoimmune diseases.

Continue

Flowonix Medical nabs about $40 mln

By Iris Dorbian — 1 year ago

Flowonix Medical has secured about $40 million in funding. The investors included Élevage Capital Management, Clarus Ventures and Hercules Technology Growth Capital. Based in NJ and Mass., Flowonix is a provider of implantable drug delivery solutions.

Continue

Imago BioSciences fetches $26.5 mln Series A

By Iris Dorbian — 1 year ago

San Francisco-based biotech firm Imago BioSciences has closed $26.5 million in Series A funding. Clarus Ventures led the round with participation from other investors that included Frazier Healthcare, Amgen Ventures and Merck Research Labs Venture Fund. In conjunction with the funding, representatives from Clarus Ventures and Frazier Healthcare have been added to the the company’s board of directors.

Continue

Breast implants seller Sientra debuts IPO

By Iris Dorbian — 1 year ago

Santa Barbara, Calif-based Sientra, a seller of breast implants, has raised $75 million for its IPO after pricing its 5 million shares at $15 per share. The stock began trading Wednesday on the NASDAQ under the ticker symbol “SIEN.” Piper Jaffray and Stifel are serving as lead underwriters. Sientra’s backers include OrbiMed Advisors, Clarus Ventures, Abingworth Management, Goldman Sachs and TIAA-CREF.

Continue

NanoString Technologies Prices IPO; VC firms Clarus, DFJ and OVP Poised for Payout

By Lawrence Aragon — 3 years ago

Venture-backed NanoString Technologies Inc. on Tuesday said that it is pricing its initial public offering of 5.4 million shares at $10 per share. The company, which makes life science tools for translational research and molecular diagnostic products, has raised a total of $82 million in venture capital since its founding in 2003. Clarus Ventures, Draper Fisher Jurvetson and OVP Venture Partners as a group own 7.4 million pre-IPO shares, or 79% of the company, according to its S-1 filing.

Continue

Boston-Based Firm Launches Eventide Healthcare & Life Sciences Fund

By Connie Loizos — 3 years ago

Eventide Asset Management, a Boston-based investment advisory firm that is “committed to biblically responsible investing,” has launched a new fund, the Eventide Healthcare & Life Sciences. The fund’s lead portfolio manager is Finny Kuruvilla, who also serves as a principal at the healthcare venture capital firm Clarus Ventures.

Continue

NanoString Technologies Completes Series E

By Angela Sormani — 3 years ago

NanoString Technologies, a provider of life science tools for translational research and developer of molecular diagnostic products, has completed a $15.3 million Series E Preferred Stock issuance. New investors in the transaction included Morgan Stanley Expansion Capital and AllianceBernstein Alternative Investment Management Group. All previous venture investors participated including Clarus Ventures, Draper Fisher Jurvetson, OVP Venture Partners, GE healthymagination Fund, BioMed Ventures, and Henri Termeer.

Continue

NanoString Technologies Appoints New CFO

By Angela Sormani — 3 years ago

NanoString Technologies, a provider of life science tools and developer of molecular diagnostics, has appointed James A. Johnson as the company’s new chief financial officer. Johnson assumes this role from Wayne Burns who will remain with the company in his new position as senior vice president, operations and administration. NanoString Technologies is backed by GE, BioMed Ventures, Clarus Ventures, Draper Fisher Jurvetson and OVP Venture Partners.

Continue

Catabasis Pharma Bags $8M More for Series A

By Jonathan Marino — 4 years ago

Massachusetts-based Catabasis Pharmaceuticals raised an additional $8 million in its Series A financing, now bringing its total funding for the round to $47.6 million. The company is developing an omega-3 conjugated compound for patients with severe hypertriglyceridemia. SV Life Sciences, Clarus Ventures, MedImmune Ventures and Advanced Technology Ventures all participated in the funding.

Continue

NanoString Inks $20M Series D

4 years ago

Seattle-based NanoString Technologies, a provider of tools for translational research and developer of molecular diagnostics, has raised $20 million in Series D financing. New investors include GE; BioMed Ventures; and Henri Termeer, the former chief executive of Genzyme Corp. All previous venture investors in NanoString also participated in the financing, including Clarus Ventures, Draper Fisher Jurvetson and OVP Venture Partners, the company said.

Continue

Cleave Biosciences Raises $42M Series A

4 years ago

Cleave Biosciences has raised $42 million in venture capital to develop new treatments for cancer. The Series A round investors include U.S. Venture Partners, 5AM Ventures, Clarus Ventures, OrbiMed Advisors and Astellas Venture Management. The financing will support multiple small molecule discovery and development programs in the area of protein homeostasis, the company said.

Continue

Restoration Robotics Seals $41M

5 years ago

Restoration Robotics, a medical device company focused on hair restoration, has closed a $41 million Series C round led by Clarus Ventures. Sutter Hill Ventures, Alloy Ventures and Interwest Partners also joined in the round, which will be used for commercialization and the launch of its technology. The company is making computer-assisted technology that enables harvesting of hair follicles during hair restoration procedures.

Continue